Efficacy and safety of camrelizumab for cervical cancer
Author Information
Author(s): Mi Xiaodong, Tuo Fei, Lin Tong
Primary Institution: Department of Obstetrics and Gynecology, First Affiliated Hospital of Jishou University, Jishou, Hunan, China
Hypothesis
What is the efficacy and safety of camrelizumab in treating cervical cancer?
Conclusion
Camrelizumab is effective and well-tolerated in patients with cervical cancer.
Supporting Evidence
- Camrelizumab showed a complete response rate of 9.7%.
- Partial response rate was 46.5%.
- Stable disease rate was 26.4%.
- Overall response rate was 57.7%.
- Disease control rate was 78.4%.
- Adverse events were mostly manageable and included anemia and fatigue.
Takeaway
This study found that a medicine called camrelizumab helps people with cervical cancer feel better and is safe to use.
Methodology
A systematic review and meta-analysis of six trials involving patients with cervical cancer treated with camrelizumab.
Potential Biases
Some studies were single-arm or retrospective, limiting the ability to draw definitive conclusions.
Limitations
The number of studies included was small, and there was significant heterogeneity among the studies.
Participant Demographics
Patients diagnosed with cervical cancer, with varying stages and treatment histories.
Statistical Information
Confidence Interval
95% CI: 0.032-0.186 for CR; 95% CI: 0.291-0.638 for PR; 95% CI: 0.124-0.403 for SD; 95% CI: 0.051-0.296 for PD; 95% CI: 0.354-0.799 for ORR; 95% CI: 0.652-0.916 for DCR.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website